Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles.
1. A composition comprising a nanoparticle, the nanoparticle comprising:
a plurality of polymers comprising
(i) at least one amphiphilic polymer comprising at least one first hydrophobic polymer and at least one hydrophilic polymer, and
(ii) at least one second hydrophobic polymer that is biodegradable and is linked to one or more platinum (Pt)-containing chemotherapeutic agents, wherein the chemotherapeutic agents are linked to one or more pendant functional groups present along a length of the second hydrophobic polymer; and
a topoisomerase inhibitor selected from the group consisting of irinotecan, SN-38, topotecan, and camptothecin;
wherein the one or more Pt-containing chemotherapeutic agents are all cisplatin;
wherein the polymers self-assemble in an aqueous liquid to form the nanoparticle, wherein the at least one first hydrophobic polymer and the at least one second hydrophobic polymer form a hydrophobic core of the nanoparticle and the at least one hydrophilic polymer forms a shell of the nanoparticle, wherein the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a synergistic ratio between about 1:4 to about 4:1, and
wherein the polymers are formulated to provide a time-dependent, condition-dependent, or both time-dependent and condition-dependent controlled release of the one or more Pt-containing chemotherapeutic agents and the topoisomerase inhibitor from the nanoparticle.
2. The composition of claim 1 , further comprising a targeting moiety linked to at least one of the polymers, wherein the targeting moiety is exposed on an outer surface of the nanoparticle.
3. The composition of claim 1 , wherein the topoisomerase inhibitor is linked to at least one of the polymers.
4. The composition of claim 2 , wherein the targeting moiety is linked to at least one of the polymers through an ester, an amide, or an ether bond.
5. The composition of claim 1 , wherein the plurality of polymers includes at least one amphiphilic polymer.
6. The composition of claim 1 , wherein the Pt-containing chemotherapeutic agent is linked to the hydrophobic polymer through an ester, an amide, or an ether bond.
7. The composition of claim 1 , wherein the nanoparticle further comprises an outer layer comprising a surfactant.
8. The composition of claim 2 , wherein:
the plurality of polymers comprises poly(lactide-co-glycolic acid)-polyethylene glycol (PLGA-PEG) and polylactic acid;
the targeting moiety is S,S-2[3-][5-amino-1-carboxypentyl]-ureido]-pentanedioic acid (LIG);
and
the topoisomerase inhibitor is irinotecan.
9. The composition of claim 1 , wherein the nanoparticle has a diameter of about 40 nm to 80 nm.
10. The composition of claim 1 , further comprising one or more additional anti-cancer agents selected from the group consisting of: an alkylating agent, an antimetabolite, an anthracycline, a plant alkyloid, and a therapeutic antibody or antigen-binding antibody fragment that specifically binds to a tumor antigen.
11. A pharmaceutical composition comprising the composition of claim 1 .
12. A method of reducing the proliferation of a cancer cell, the method comprising contacting a cancer cell with an amount of the composition of claim 1 sufficient to reduce the proliferation of the cancer cell.
13. A method of making a nanoparticle according to claim 1 , the method comprising:
mixing (i) a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer linked to a platinum (Pt)-containing chemotherapeutic agent; and (ii) a topoisomerase inhibitor in an organic solvent to form an organic precursor solution; and
contacting the organic precursor solution with an aqueous solvent to achieve a ratio of 5:1 to 20:1 volume of organic precursor solution to volume of aqueous solvent, wherein the contacting results in the self-assembly of a nanoparticle.
14. The method of claim 13 , wherein the plurality of polymers further comprises at least one polymer linked to a targeting moiety.
15. The method of claim 13 , wherein the topoisomerase inhibitor is linked to at least one of the polymers.
16. The method of claim 14 , wherein:
the plurality of copolymers comprises poly (lactide-co-glycolic acid) polyethylene glycol (PLGA-PEG) and polylactic acid (PLA);
the targeting moiety is S,S-2[3-][5-amino-1-carboxypentyl]-ureido]-pentanedioic acid (LIG);
the Pt-containing chemotherapeutic agent is cisplatin; and
the topoisomerase inhibitor is irinotecan.
17. A composition comprising a nanoparticle, the nanoparticle comprising:
a plurality of polymers comprising
(i) at least one amphiphilic polymer comprising at least one first hydrophobic polymer and at least one hydrophilic polymer, and
(ii) at least one second hydrophobic polymer that is biodegradable and is linked to one or more topoisomerase inhibitors and to one or more platinum (Pt)-containing chemotherapeutic agents, wherein the Pt-containing chemotherapeutic agents and topoisomerase inhibitors are linked to one or more pendant functional groups present along a length of the biodegradable hydrophobic polymer; wherein the polymers self-assemble in an aqueous liquid to form the nanoparticle, wherein the at least one first hydrophobic polymer and the at least one second hydrophobic polymer form a hydrophobic core of the nanoparticle and the at least one hydrophilic polymer forms a shell of the nanoparticle,
wherein the one or more Pt-containing chemotherapeutic agents are all cisplatin;
wherein the topoisomerase inhibitor is selected from the group consisting of irinotecan, SN-38, topotecan, and camptothecin;
wherein the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a synergistic ratio between about 1:4 to about 4:1, and
wherein the polymers are formulated to provide a time-dependent, condition-dependent, or both time-dependent and condition-dependent controlled release of the one or more Pt-containing chemotherapeutic agents and the topoisomerase inhibitor from the nanoparticle.
18. The composition of claim 1 , wherein the pendant functional groups of the hydrophobic polymer comprise any one or more of hydroxyl, carboxyl, amine, amide, carbamate, maleimide, thiol, halide, azide, proparzyl, or allyl functional groups.
19. The composition of claim 17 , wherein the pendant functional groups of the hydrophobic polymer comprise any one or more of hydroxyl, carboxyl, amine, amide, carbamate, maleimide, thiol, halide, azide, proparzyl, or allyl functional groups.
20. The composition of claim 1 , wherein the hydrophobic polymer comprises approximately one pendant functional group for every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, or 20 monomer units.
21. The composition of claim 17 , wherein the hydrophobic polymer comprises approximately one pendant functional group for every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, or 20 monomer units.
22. The composition of claim 1 , wherein the first hydrophobic polymer is also biodegradable and wherein the (Pt)-containing chemotherapeutic agents are also linked to one or more pendant functional groups present along a length of the first hydrophobic polymer.
23. The composition of claim 17 , wherein the first hydrophobic polymer is also biodegradable and wherein the (Pt)-containing chemotherapeutic agents and topoisomerase inhibitors are also linked to one or more pendant functional groups present along a length of the first hydrophobic polymer.